Vector VestAdvertisement
Home > Boards > US OTC > Biotechs >

Amarantus BioScience Holdings, Inc. (AMBS)

AMBS RSS Feed
Add AMBS Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator joboggi, zoomboom, Rosym
Search This Board:
Last Post: 1/31/2015 10:25:02 PM - Followers: 721 - Board type: Free - Posts Today: 0



Amarantus BioScience Holdings, Inc.

   Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis.
   The company has licensed Eltoprazine, a Phase 2B ready Parkinsons Levadopa induced Dyskinesia.
   The company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") for Alzheimer's Disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders.
   Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders.
   The Company also owns intellectual property rights for the diagnosis of Parkinson's Disease ("NuroPro") and the discovery of neurotrophic facotrs ("PhenoGuard").

ESS, previously known as PermaDerm®  is being developed to be the only tissue-engineered skin prepared from autologous (patient's own) skin cells consisting of both epidermal and dermal layers. A small harvested section of the patient's own skin can be grown to graft an area one hundred times its size in as little as thirty days. 

DioGenix has preliminary data that suggests our technical approach to MS can be expanded to better understand and improve decision making in other neurological and neurodegenerative diseases, including: Neuro-sarciod, Neuromyelitis optica, Paraneoplastic disease and Lupus with neurological involvement.   For further information, please visit www.Amarantus.comor connect with the company in FacebookTwitter, LinkedIn & Google+



 

          


 
PRESS RELEASES & NEWS ARTICLES

Amarantus Diagnostics - First-Mover Advantage in the $3B Alzheimer’s Blood Test Market with a Business Strategy for Significant Near-Term Revenue in Multiple Sclerosis to Bridge the Gap
January 28th, 2015
Amarantus Forms Alzheimer's Disease Diagnostics Scientific Advisory Board
Jan. 22, 2015
Amarantus Announces Exclusive Option Agreement With Georgetown University to License Patent Rights for Blood Based Biomarkers for Alzheimer's Disease
Jan. 15, 2015
Amarantus to Present at Noble Financial Capital Markets' Eleventh Annual Investor Conference
Jan. 13, 2015
Amarantus Announces Acquisition of Specialized Neuro-Diagnostics Company, DioGenix
Jan. 12, 2015
Amarantus to Participate in the Eighth Annual OneMedForum Conference on January 12 - 13, 2015
Jan. 8, 2015
Jason Napodano - 15 Biotech Names For 2015 
Jan. 5, 2015
Amarantus to Present LP-002 Data for Alzheimer's Blood Diagnostic LymPro Test(R) at Biotech Showcase 2015 Conference on January 14, 2015
Dec. 29, 2014
Amarantus Receives Orphan Drug Designation for MANF From U.S. Food and Drug Administration for Treatment of Retinitis Pigmentosa
Dec. 23, 2014
Amarantus Receives Orphan Drug Designation for MANF in Retinitis Pigmentosa
December 23, 2014
Amarantus Diagnostics: Launching our First Product in the Neurodiagnostics Market
Dec. 22, 2014
Amarantus Commences Launch of Proprietary Alzheimer's Blood Diagnostic LymPro Test(R) to Pharmaceutical Industry for Use in Clinical Trials
Dec. 22, 2014
Amarantus Announces Second Closing of Series E Preferred Financing
Dec. 19, 2014 
Amarantus Submits Orphan Drug Designation Application to US FDA for Treatment of Retinal Artery Occlusion With Product Candidate MANF
Dec. 19, 2014
Amarantus Appoints Elise Brownell, Ph.D., as Senior Vice President of Operations and Project Management
Dec. 11, 2014
Amarantus Appoints Renowned Drug Development Expert and Co-Founder of Amgen, Joseph Rubinfeld, Ph.D., to Its Board of Directors
Dec. 8, 2014
Amarantus Announces Positive Preclinical Data on the Effects of MANF on Vision in a Model of Retinitis Pigmentosa
Nov. 25, 2014

Developing an Accurate Test for Multiple Sclerosis

 Mar 5, 2014

 

December 12, 2014
SNNLive - Amarantus BioScience Holdings, Inc.

 

Oct. 19, 2014
Amarantus BioSciences






 
 
 
    
       

 

Company Information

Investor Relations

Transfer Agent

Amarantus BioScience Holdings, Inc.
c/o Janssen Labs @ QB3
953 Indiana Street
San Francisco, CA 94107

c/o ICS Corporate Services SA
29 quai du Mont Blanc
CH-1201 Geneva
Switzerland

info@amarantus.com
pr@amarantus.com


Phone: (408) 737-2734
Fax: (408) 852-4427

Aimee Boutcher
Director of Investor Relations
Amarantus BioScience Holdings, Inc
.

408-737-2734 x101
ir@amarantus.com


Gerald's email address

Gerald@amarantus.com







 
VStock Transfer, LLC
77 Spruce Street, Suite 201
Cedarhurst, NY 11516

Attn: Allison Niccols


Phone: 212-828-8436
Toll-Free: 855-9VSTOCK
Fax: 646-536-3179

info@vstocktransfer.com

www.VStockTransfer.com 


 
 
smiley  "Amarantus is aiming to be first to market with an accurate, reliable and commercially- viable diagnostic blood test for Alzheimer's disease," said Gerald E. Commissiong. "Today's data gives us all the information we need to move full steam ahead with this strategy. We can now tailor our initial marketing efforts towards the $150M RUO market, primarily targeting pharmaceutical companies engaged in Alzheimer's disease therapeutic trials. We have nearly completed assembling the resources needed to launch LymPro to the RUO community by the year-end 2014. Thereafter, we intend to market LymPro to the broader medical community, initially under CLIA. We estimate the worldwide market for an Alzheimer's diagnostic is $3B"
 
  Amarantus Receives Orphan Drug Designation for MANF From U.S. Food and Drug Administration for Treatment of Retinitis Pigmentosa
 "We are very pleased to receive orphan drug designation for MANF in RP. This represents an important milestone for the company as well as a significant step forward for our clinical and regulatory strategy," said Gerald E. Commissiong
 Most people with RP are legally blind by age 40. It is estimated that the market opportunity for Retinitis Pigmentosa exceeds $10B annually.

 
“I believe in MANF,” said Dr. Rubinfeld, “I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen”   Finally, the company's Alzheimer's blood diagnostic LymPro Test® is slated to become the world's first effective Alzheimer's blood test, expected to establish a market leading position under the Clinical Laboratory Improvement Amendments, and will be available before the end of 2014 for Investigational Use Only to assist the biopharmaceutical industry in its therapeutic Alzheimer's development programs."  cool
 
smiley   Gerald E. Commissiong  -  We recognize that it is not optimal to up list from a position of weakness, and therefore we will only consider an up list from a position of strength while the Company is making good progress in the market. We believe the milestones we’ve outlined above and will put us in that position. However, if we do not believe we have achieved sufficient shareholder value creation, we will consider delaying the up list until such time as the market recognizes our true value.
 
 
President & CEO, Gerald E. Commissiong - Noble Financial Capital Markets' Jan. 19, 2015 
Live audio webcasts
 
smiley Click here:  On January 13, 2015, Amarantus BioScience Holdings, Inc. (the “Company”) entered into an Exclusive Option Agreement (the “Agreement”) with the Georgetown University (“Georgetown”) pursuant to which the Company was granted an option (the “Option”) to obtain an exclusive license (with the right to sublicense) from Georgetown based upon certain patented technologies entitled “BLOOD BASED BIOMARKERS FOR MEMORY LOSS” (the “Technologies”). The term of the option is 12 months (the “Term”) which may be extended mutual written consent of the parties. In consideration for the grant of the option, the Company shall pay an option fee of $75,000.
 
 
heart Amarantus BioScience  Participate in the Bio CEO & Investor Coference heart
Feb. 10, 2015
at 8:30-8:55 a.m4th Floor Trevena Conference Room 

Hotel Venue The Waldorf Astoria New York 301 Park Avenue New York, NY 10022
Now in its 17th year,the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. 
BIO’s One-on-One Partnering™ System is the interactive environment that allows you to increase your productivity, discover new investment and licensing opportunities, and expand your business potential worldwide. Using the system, companies are able to: • Pre-schedule 30-minute private 1x1 meetings • Source potential collaborations and funding opportunities with an international audience • Communicate directly with prospective investors and C-level executives in biotech and pharma • Search company and investor profiles for potential business partnerships
BIO will be previewing its next generation Partnering System, intended to launch at the 2015 BIO International Convention. To learn more, visit us at the partnering desk during the BIO CEO & Investor Conference. 

2015 Participating Companies

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AMBS
Current Price
Volume:
Bid Ask Day's Range
Wiki
AMBS News: Current Report Filing (8-k) 01/15/2015 04:17:14 PM
AMBS News: Current Report Filing (8-k) 01/15/2015 06:02:14 AM
AMBS News: Statement of Changes in Beneficial Ownership (4) 01/15/2015 06:02:14 AM
AMBS News: Statement of Changes in Beneficial Ownership (4) 01/14/2015 05:25:12 PM
AMBS News: Statement of Changes in Beneficial Ownership (4) 01/14/2015 05:22:29 PM
PostSubject
#110746  Sticky Note Jason Napodano - 15 Biotech Names For 2015 Rosym 01/05/15 04:13:55 PM
#104968  Sticky Note MJFF is firm with their notion that NFs joboggi 07/17/14 02:01:07 AM
#111387   AMBS has MANF patent on wound healing. zoomboom 01/31/15 10:25:02 PM
#111385   it's been over 1 year since Dr. Robert JPetroInc 01/31/15 05:04:35 PM
#111384   why would Dr. Robert Stern of BU Medical JPetroInc 01/31/15 04:41:16 PM
#111383   http://www.ddn-news.com/index.php?newsarticle=9193#AMBS Going aft Rosym 01/31/15 10:52:44 AM
#111382   when MANF is proven to work in human JPetroInc 01/31/15 09:04:32 AM
#111381   $AMBS MANF -Medscape Article -Orphan drug approval. In zoomboom 01/30/15 10:45:48 PM
#111380   Silent accumulation? Lonnie Dillard 01/30/15 01:50:41 PM
#111379   I guess the 5000 viewers of cnn could shamalam 01/30/15 09:58:32 AM
#111377   Big wave of sprinters coming myersvodka 01/30/15 09:29:04 AM
#111376   Prepare for lift off myersvodka 01/30/15 09:27:57 AM
#111375   CNN you kidding me. FOX BUSINESS NEWS is klouis 01/30/15 03:36:18 AM
#111374   I realize that, but I posted so that joboggi 01/30/15 02:22:04 AM
#111373   All fair game that's in the cross hairs Sir JPetroInc 01/29/15 11:06:18 PM
#111372   1. I did ask Sol. I would like joboggi 01/29/15 11:03:53 PM
#111370   Hey JP...we are all in this together....glad to Salexander1 01/29/15 09:08:15 PM
#111369   well spoken as usual Sal....... JPetroInc 01/29/15 08:46:35 PM
#111368   answer to question no. 1 JPetroInc 01/29/15 08:42:05 PM
#111367   Higher Volume always precedes price movement...if this new Salexander1 01/29/15 06:06:16 PM
#111366   1. What is the catalyst for this predicted move? joboggi 01/29/15 05:18:49 PM
#111365   Interesting little flurry of buying. Agreed it didn't brharris 01/29/15 01:15:18 PM
#111364   Two things you need to know: Solantey 01/29/15 12:53:40 PM
#111363   Wow what's up myersvodka 01/29/15 12:38:41 PM
#111362   0,085 some news? ron51ron51 01/29/15 12:35:42 PM
#111361  Restored This is not retail taking this a click JPetroInc 01/29/15 12:23:52 PM
#111360   Unfortunately Gerald "double talked" his loyal and ardent JPetroInc 01/29/15 11:30:03 AM
#111359   Two years of thumb twiddling here shamalam 01/29/15 10:24:39 AM
#111358   Gerald will need to reinvent himself when catering JPetroInc 01/29/15 07:03:28 AM
#111357   http://www.thechairmansblog.com/amarantus-bioscience/gerald-commissiong/amarantu brharris 01/28/15 07:50:50 PM
#111353   Explain? JCWH 01/28/15 06:38:16 PM
#111352   Looks like dividends of shares are coming myersvodka 01/28/15 04:51:54 PM
#111351   The selling of cheap shares is a major JPetroInc 01/28/15 04:08:00 PM
#111348   they have several offers on the table NOW!!! Alapis 01/28/15 10:03:05 AM
#111346   Spin-out possibility ???????? ron51ron51 01/28/15 09:29:28 AM
#111345   "We truly believe 2015 will be a monumental Alapis 01/28/15 09:20:28 AM
#111344   I'm anything else but a fan from GC Alapis 01/28/15 09:16:14 AM
#111343   New chairmans blog: zynomat 01/28/15 09:06:47 AM
#111342   So very true. Zero emotions. Just facts.....whether good Zaadx 01/28/15 08:46:27 AM
#111341   I've come to learn the hard way that JPetroInc 01/28/15 06:54:03 AM
#111340  Restored with a 'college lunch money' cult following, AMBS JPetroInc 01/28/15 06:45:17 AM
#111339   Gerald could have used entire 23 mil of GS1 01/28/15 06:12:42 AM
#111338   In words simple enough for you to understand, JPetroInc 01/28/15 03:22:05 AM
#111337   https://www.bio.org/sites/default/files/CEO2015_eBrochure.pdf GS1 01/28/15 01:46:20 AM
#111336   You have to admit that Gerald "spins a Solantey 01/28/15 01:27:41 AM
#111331   I personally hold boy Gerald accountable for the JPetroInc 01/27/15 05:28:37 PM
#111330   The hype surrounding AMBS presented an opportunity for joboggi 01/27/15 04:16:14 PM
#111325  Restored Woooow. You can lose a lot of money Zaadx 01/27/15 10:37:32 AM
#111324   well he does not doo his dd...soon we Alapis 01/27/15 09:58:28 AM
#111323   Since when did garbages start to receive orphan Titan V 01/27/15 09:56:30 AM
#111322   TOXIC FINANCER Dominion is the LARGEST shareholder Sgt. Pepper 01/27/15 09:23:47 AM
#111320   One other quick thought. AMBS has access brharris 01/27/15 08:59:24 AM
PostSubject